VERTEX PHARMACEUTICALS INC / MA (VRTX) Free cash flow
- Free cash flow · 12 months (USD): Value $3.80B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 30.16%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $3.80B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $4.29B − $496.80M ≈ $3.80B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 30.16% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $3.80B ÷ $12.59B × 100 ≈ 30.16% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $4.29B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.97× | Operating cash flow / net income. Period ending 2026-06-30. $4.29B ÷ $4.41B ≈ 0.97× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 4.29B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 496.80M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 3.80B USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 12.59B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 4.41B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.80B | (m) | $4.29B | $496.80M | (m) | $12.59B | (m) | $4.41B | (m) | (m) | 30.16% | 0.97× |
| 2026-03-31 | $3.71B | (m) | $4.24B | $530.30M | (m) | $12.22B | (m) | $4.34B | (m) | (m) | 30.37% | 0.98× |
| 2025-12-31 | $3.19B | (m) | $3.63B | $437.60M | (m) | $12.00B | (m) | $3.95B | (m) | (m) | 26.61% | 0.92× |
| 2025-09-30 | $3.34B | (m) | $3.72B | $380.80M | (m) | $11.72B | (m) | $3.68B | (m) | (m) | 28.47% | 1.01× |
| 2025-06-30 | $3.50B | (m) | $3.85B | $346.70M | (m) | $11.42B | (m) | $3.64B | (m) | (m) | 30.65% | 1.06× |
| 2025-03-31 | $-1.25B | (m) | $-980.30M | $270.00M | (m) | $11.10B | (m) | $-988.90M | (m) | (m) | -11.26% | 0.99× |
| 2024-12-31 | $-790.30M | (m) | $-492.60M | $297.70M | (m) | $11.02B | (m) | $-535.60M | (m) | (m) | -7.17% | 0.92× |
| 2024-09-30 | $-1.11B | (m) | $-842.60M | $263.20M | (m) | $10.63B | (m) | $-479.80M | (m) | (m) | -10.41% | 1.76× |
| 2024-06-30 | $-1.18B | (m) | $-944.00M | $236.10M | (m) | $10.34B | (m) | $-489.90M | (m) | (m) | -11.42% | 1.93× |
| 2024-03-31 | $3.72B | (m) | $3.94B | $226.70M | (m) | $10.19B | (m) | $4.02B | (m) | (m) | 36.50% | 0.98× |
| 2023-12-31 | $3.34B | (m) | $3.54B | $200.40M | (m) | $9.87B | (m) | $3.62B | (m) | (m) | 33.81% | 0.98× |
| 2023-09-30 | $4.21B | (m) | $4.38B | $175.90M | (m) | $9.65B | (m) | $3.47B | (m) | (m) | 43.56% | 1.26× |
| 2023-06-30 | $3.88B | (m) | $4.07B | $189.50M | (m) | $9.51B | (m) | $3.36B | (m) | (m) | 40.81% | 1.21× |
| 2023-03-31 | $3.89B | (m) | $4.07B | $183.20M | (m) | $9.21B | (m) | $3.26B | (m) | (m) | 42.25% | 1.25× |
| 2022-12-31 | $3.93B | (m) | $4.13B | $204.70M | (m) | $8.93B | (m) | $3.32B | (m) | (m) | 43.95% | 1.24× |
| 2022-09-30 | $3.81B | (m) | $4.05B | $232.90M | (m) | $8.70B | (m) | $3.27B | (m) | (m) | 43.83% | 1.24× |
| 2022-06-30 | $3.79B | (m) | $4.02B | $231.10M | (m) | $8.35B | (m) | $3.19B | (m) | (m) | 45.35% | 1.26× |
| 2022-03-31 | $2.45B | (m) | $2.68B | $227.70M | (m) | $7.95B | (m) | $2.45B | (m) | (m) | 30.84% | 1.09× |
| 2021-12-31 | $2.41B | (m) | $2.64B | $235.00M | (m) | $7.57B | (m) | $2.34B | (m) | (m) | 31.80% | 1.13× |
| 2021-09-30 | $1.92B | (m) | $2.14B | $220.97M | (m) | $7.13B | (m) | $2.18B | (m) | (m) | 26.92% | 0.98× |
| 2021-06-30 | $1.78B | (m) | $2.12B | $343.25M | (m) | $6.68B | (m) | $1.99B | (m) | (m) | 26.59% | 1.06× |
| 2021-03-31 | $3.05B | (m) | $3.36B | $311.27M | (m) | $6.41B | (m) | $2.76B | (m) | (m) | 47.51% | 1.22× |
| 2020-12-31 | $2.99B | (m) | $3.25B | $259.80M | (m) | $6.21B | (m) | $2.71B | (m) | (m) | 48.24% | 1.20× |
| 2020-09-30 | $2.98B | (m) | $3.21B | $228.87M | (m) | $5.99B | (m) | $2.69B | (m) | (m) | 49.73% | 1.19× |
| 2020-06-30 | $2.56B | (m) | $2.64B | $78.37M | (m) | $5.40B | (m) | $2.08B | (m) | (m) | 47.32% | 1.27× |
| 2020-03-31 | $1.98B | (m) | $2.06B | $76.86M | (m) | $4.82B | (m) | $1.51B | (m) | (m) | 41.15% | 1.36× |
| 2019-12-31 | $1.49B | (m) | $1.57B | $75.45M | (m) | $4.16B | (m) | $1.18B | (m) | (m) | 35.89% | 1.33× |
| 2019-09-30 | $1.36B | (m) | $1.44B | $74.41M | (m) | $3.62B | (m) | $2.14B | (m) | (m) | 37.67% | 0.67× |
| 2019-06-30 | $1.41B | (m) | $1.48B | $71.03M | (m) | $3.45B | (m) | $2.22B | (m) | (m) | 40.92% | 0.67× |
| 2019-03-31 | $1.26B | (m) | $1.34B | $84.29M | (m) | $3.27B | (m) | $2.16B | (m) | (m) | 38.53% | 0.62× |
| 2018-12-31 | $1.17B | (m) | $1.27B | $95.52M | (m) | $3.05B | (m) | $2.10B | (m) | (m) | 38.55% | 0.61× |
| 2018-09-30 | $1.06B | (m) | $1.18B | $122.79M | (m) | $2.83B | (m) | $647.05M | (m) | (m) | 37.48% | 1.83× |
| 2018-06-30 | $842.12M | (m) | $971.96M | $129.84M | (m) | $2.62B | (m) | $415.36M | (m) | (m) | 32.11% | 2.34× |
| 2018-03-31 | $714.31M | (m) | $831.91M | $117.60M | (m) | $2.41B | (m) | $225.99M | (m) | (m) | 29.58% | 3.68× |
| 2017-12-31 | $745.52M | (m) | $844.94M | $99.42M | (m) | $2.49B | (m) | $263.48M | (m) | (m) | 29.96% | 3.21× |
| 2017-09-30 | $690.55M | (m) | $762.15M | $71.61M | (m) | $2.30B | (m) | $195.75M | (m) | (m) | 30.08% | 3.89× |
| 2017-06-30 | $600.19M | (m) | $657.73M | $57.54M | (m) | $2.13B | (m) | $259.86M | (m) | (m) | 28.16% | 2.53× |
| 2017-03-31 | $461.18M | (m) | $516.93M | $55.75M | (m) | $2.02B | (m) | $177.34M | (m) | (m) | 22.84% | 2.92× |
| 2016-12-31 | $179.54M | (m) | $236.10M | $56.56M | (m) | $1.70B | (m) | $-112.05M | (m) | (m) | 10.55% | -2.11× |
| 2016-09-30 | $66.22M | (m) | $120.52M | $54.30M | (m) | $1.66B | (m) | $-218.73M | (m) | (m) | 3.99% | -0.55× |
| 2016-06-30 | $-56.42M | (m) | $-7.21M | $49.22M | (m) | $1.56B | (m) | $-275.04M | (m) | (m) | -3.62% | 0.03× |
| 2016-03-31 | $-205.05M | (m) | $-158.33M | $46.72M | (m) | $1.29B | (m) | $-399.36M | (m) | (m) | -15.87% | 0.40× |
| 2015-12-31 | $-410.73M | (m) | $-365.43M | $45.30M | (m) | $1.03B | (m) | $-556.33M | (m) | (m) | -39.79% | 0.66× |
| 2015-09-30 | $-518.74M | (m) | $-471.29M | $47.45M | (m) | $758.96M | (m) | $-659.26M | (m) | (m) | -68.35% | 0.71× |
| 2015-06-30 | $-559.86M | (m) | $-511.91M | $47.95M | (m) | $628.13M | (m) | $-734.17M | (m) | (m) | -89.13% | 0.70× |
| 2015-03-31 | $-590.85M | (m) | $-544.62M | $46.23M | (m) | $600.47M | (m) | $-704.70M | (m) | (m) | -98.40% | 0.77× |
| 2014-12-31 | $-564.40M | (m) | $-513.20M | $51.20M | (m) | $580.41M | (m) | $-738.55M | (m) | (m) | -97.24% | 0.69× |
| 2014-09-30 | $-413.47M | (m) | $-362.47M | $51.00M | (m) | $787.02M | (m) | $-517.61M | (m) | (m) | -52.54% | 0.70× |
| 2014-06-30 | $-348.76M | (m) | $-288.55M | $60.21M | (m) | $829.73M | (m) | $-471.69M | (m) | (m) | -42.03% | 0.61× |
| 2014-03-31 | $-211.87M | (m) | $-161.55M | $50.31M | (m) | $1.00B | (m) | $-369.47M | (m) | (m) | -21.14% | 0.44× |
| 2013-12-31 | $-102.96M | (m) | $-51.57M | $51.39M | (m) | $1.21B | (m) | $-445.03M | (m) | (m) | -8.50% | 0.12× |
| 2013-09-30 | $-104.83M | (m) | $-39.87M | $64.97M | (m) | $1.19B | (m) | $-565.46M | (m) | (m) | -8.77% | 0.07× |
| 2013-06-30 | $11.96M | (m) | $79.81M | $67.85M | (m) | $1.31B | (m) | $-498.87M | (m) | (m) | 0.91% | -0.16× |
| 2013-03-31 | $117.56M | (m) | $199.15M | $81.59M | (m) | $1.42B | (m) | $-506.64M | (m) | (m) | 8.30% | -0.39× |
| 2012-12-31 | $196.70M | (m) | $267.84M | $71.14M | (m) | $1.53B | (m) | $-107.03M | (m) | (m) | 12.88% | -2.50× |
| 2012-09-30 | $678.52M | (m) | $730.95M | $52.42M | (m) | $1.76B | (m) | $127.75M | (m) | (m) | 38.63% | 5.72× |
| 2012-06-30 | $626.87M | (m) | $667.88M | $41.01M | (m) | $2.08B | (m) | $406.40M | (m) | (m) | 30.14% | 1.64× |
| 2012-03-31 | $297.38M | (m) | $333.28M | $35.90M | (m) | $1.78B | (m) | $297.26M | (m) | (m) | 16.75% | 1.12× |
| 2011-12-31 | $109.14M | (m) | $143.74M | $34.59M | (m) | $1.41B | (m) | $29.57M | (m) | (m) | 7.74% | 4.86× |
| 2011-09-30 | $-565.73M | (m) | $-526.03M | $39.69M | (m) | $912.81M | (m) | (m) | (m) | (m) | -61.98% | (m) |
| 2011-06-30 | $-773.46M | (m) | $-732.92M | $40.54M | (m) | $277.40M | (m) | (m) | (m) | (m) | -278.82% | (m) |
| 2011-03-31 | $-665.40M | (m) | $-625.61M | $39.79M | (m) | $194.60M | (m) | (m) | (m) | (m) | -341.93% | (m) |
| 2010-12-31 | $-673.50M | (m) | $-635.44M | $38.05M | (m) | $143.37M | (m) | (m) | (m) | (m) | -469.76% | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-451.08M | (m) | $-427.59M | $23.50M | (m) | $101.89M | (m) | (m) | (m) | (m) | -442.72% | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-258.66M | (m) | $-226.48M | $32.18M | (m) | $175.50M | (m) | (m) | (m) | (m) | -147.38% | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |